A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (NCT05269004)
A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study To Evaluate The Long-Term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046) are eligible for enrollment in this extension study. Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.
Who can join: Review the eligibility criteria below.
Location: Barrow Neurological Institute — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (236 Sites)
Showing the first 25 of 236 sites.
- Barrow Neurological Institute — Phoenix, Arizona
- Arizona Neuroscience Research LLC — Phoenix, Arizona
- MS Center of California — Laguna Hills, California
- Stanford Hospital and Clinics — Palo Alto, California
- University of California San Francisco — San Francisco, California
- University of California San Francisco — San Francisco, California
- University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center) — Aurora, Colorado
- Advanced Neurosciences Research LLC — Fort Collins, Colorado
- Neurology Associates PA — Maitland, Florida
- University of Miami — Miami, Florida
- Neurological Services of Orlando — Orlando, Florida
- University of South Florida — Tampa, Florida
- Vero Beach Neurology and Research Institute — Vero Beach, Florida
- Atlanta Neuroscience Institute — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- Consultants in Neurology Ltd — Northbrook, Illinois
- Indiana Univ School of Med — Indianapolis, Indiana
- Kansas University Medical Center — Kansas City, Kansas
- Massachusetts General Hospital — Boston, Massachusetts
- Wayne State University — Detroit, Michigan
- Henry Ford Hospital — Detroit, Michigan
- Michigan Institute for Neurological Disorders — Farmington Hills, Michigan
- Minneapolis Clinic of Neurology — Golden Valley, Minnesota
- University of Minnesota — Minneapolis, Minnesota
- Washington University — St Louis, Missouri
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis — Birmingham, Alabama
- MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience — New Orleans, Louisiana
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Carlsbad, California
- The Synergistic Effects of AIH and FES in Persons With MS — Chicago, Illinois
- A Health Action Process Approach Online Intervention for People With Multiple Sclerosis — Champaign, Illinois
Explore by condition: All Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.